161 related articles for article (PubMed ID: 27719721)
41. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.
Sugio T; Miyawaki K; Kato K; Sasaki K; Yamada K; Iqbal J; Miyamoto T; Ohshima K; Maeda T; Miyoshi H; Akashi K
Blood Adv; 2018 Sep; 2(17):2242-2252. PubMed ID: 30194138
[TBL] [Abstract][Full Text] [Related]
42. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression.
Quintanilla-Martinez L; Franklin JL; Guerrero I; Krenacs L; Naresh KN; Rama-Rao C; Bhatia K; Raffeld M; Magrath IT
Hum Pathol; 1999 Jul; 30(7):849-55. PubMed ID: 10414505
[TBL] [Abstract][Full Text] [Related]
43. Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Review of Current Disease Understanding and Therapeutic Approaches.
Al-Zahrani M; Savage KJ
Hematol Oncol Clin North Am; 2017 Apr; 31(2):189-207. PubMed ID: 28340873
[TBL] [Abstract][Full Text] [Related]
44. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
Vose J; Armitage J; Weisenburger D;
J Clin Oncol; 2008 Sep; 26(25):4124-30. PubMed ID: 18626005
[TBL] [Abstract][Full Text] [Related]
45. [Amplification and specific expression of T-bet gene in nasal NK/T cell lymphoma].
Ye YH; Li T; Qi WX; Guo ZQ; Zhang B
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(13):881-5. PubMed ID: 16759512
[TBL] [Abstract][Full Text] [Related]
46. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
[TBL] [Abstract][Full Text] [Related]
47. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Oki Y
PLoS One; 2018; 13(3):e0191461. PubMed ID: 29538376
[TBL] [Abstract][Full Text] [Related]
48. Distinct morphologic, phenotypic, and clinical-course characteristics of indolent peripheral T-cell lymphoma.
Hayashi E; Takata K; Sato Y; Tashiro Y; Tachiyama Y; Sawada-Kitamura S; Hiramatsu Y; Sugiguchi S; Nose S; Hirokawa M; Ando M; Abd Alkader L; Maeda Y; Tanimoto M; Yoshino T
Hum Pathol; 2013 Sep; 44(9):1927-36. PubMed ID: 23706909
[TBL] [Abstract][Full Text] [Related]
49. CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry.
Yuan CM; Vergilio JA; Zhao XF; Smith TK; Harris NL; Bagg A
Hum Pathol; 2005 Jul; 36(7):784-91. PubMed ID: 16084948
[TBL] [Abstract][Full Text] [Related]
50. [Analysis of mature T-cell and NK-cell lymphoma with CD30 expression based on latest WHO classification].
Feng Y; Fu J; Yan S; Ling Y; Huang Y; Cai M; Rao H
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):508-11. PubMed ID: 25346118
[TBL] [Abstract][Full Text] [Related]
51. [Expression of CDK6 and FOXM1 in peripheral T-cell lymphoma and their significance].
Feng HN; Shao XX; Bu P; Zhang F; Wang YJ; Xi YF; Guo WN
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):594-600. PubMed ID: 32486537
[No Abstract] [Full Text] [Related]
52. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Quesada AE; Nguyen ND; Rios A; Brown RE
Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
[TBL] [Abstract][Full Text] [Related]
53. [Clinical significance of survivin expression in peripheral T-cell lymphoma].
Xiang XJ; He YJ; Li YH; Huang H; Xu F
Ai Zheng; 2006 Jun; 25(6):758-61. PubMed ID: 16764776
[TBL] [Abstract][Full Text] [Related]
54. Amplification and specific expression of T-bet gene in nasal NK/T-cell lymphoma.
Ye Y; Li T; Zhang B; Guo Z
Leuk Lymphoma; 2007 Jan; 48(1):168-73. PubMed ID: 17325860
[TBL] [Abstract][Full Text] [Related]
55. Epstein-Barr virus-positive nodal peripheral T cell lymphomas: clinicopathologic and gene expression profiling study.
Ha SY; Sung J; Ju H; Karube K; Kim SJ; Kim WS; Seto M; Ko YH
Pathol Res Pract; 2013 Jul; 209(7):448-54. PubMed ID: 23735590
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS.
Cao Z; Wang X; Xue X; Feng X
Ann Hematol; 2024 Mar; 103(3):869-883. PubMed ID: 38040859
[TBL] [Abstract][Full Text] [Related]
57. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.
Zhang H; Lv H; Jia X; Hu G; Kong L; Zhang T; Li L; Pan Y; Zhai Q; Meng B; Wang X; Wang H; Wang X
Oncol Lett; 2019 Aug; 18(2):1415-1423. PubMed ID: 31423206
[TBL] [Abstract][Full Text] [Related]
58. STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas.
Yoshida N; Tsuzuki S; Karube K; Takahara T; Suguro M; Miyoshi H; Nishikori M; Shimoyama M; Tsukasaki K; Ohshima K; Seto M
Cancer Sci; 2015 Oct; 106(10):1455-62. PubMed ID: 26176172
[TBL] [Abstract][Full Text] [Related]
59. Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas.
Jung JT; Kim DH; Kwak EK; Kim JG; Park TI; Sohn SK; Do YR; Kwon KY; Song HS; Park EH; Lee KB
Ann Hematol; 2006 Sep; 85(9):575-81. PubMed ID: 16673127
[TBL] [Abstract][Full Text] [Related]
60. Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma.
Cortes JR; Filip I; Albero R; Patiño-Galindo JA; Quinn SA; Lin WW; Laurent AP; Shih BB; Brown JA; Cooke AJ; Mackey A; Einson J; Zairis S; Rivas-Delgado A; Laginestra MA; Pileri S; Campo E; Bhagat G; Ferrando AA; Rabadan R; Palomero T
Cell Rep; 2022 Apr; 39(3):110695. PubMed ID: 35443168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
